New hope for kids with returning leukemia: blinatumomab trial underway

NCT ID NCT06054113

First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times

Summary

This study tests a drug called blinatumomab in Chinese children (ages 1 month to 18 years) whose B-cell acute lymphoblastic leukemia has come back or not responded to standard treatment. The goal is to see if the drug can bring about a complete remission. The trial involves 18 participants and monitors safety and drug levels in the body.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Children's Hospital of Soochow University

    Suzhou, Jiangsu, 215002, China

  • Childrens Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400015, China

  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, 300020, China

  • Shanghai Children's Medical Center

    Shanghai, Shanghai Municipality, 200127, China

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, 230601, China

  • Wuhan Childrens Hospital

    Wuhan, Hubei, 430015, China

  • Zhujiang Hospital of Southern Medical University

    Guangzhou, Guangdong, 510280, China

Conditions

Explore the condition pages connected to this study.